# A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

> **NCT03797261** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 9 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Non-Hodgkin's Lymphoma
- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** AMG 176

## Key facts

- **NCT ID:** NCT03797261
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-18
- **Primary completion:** 2019-12-30
- **Final completion:** 2019-12-30
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Safety
- **Last updated:** 2021-12-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03797261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03797261, "A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03797261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*